Diplomat Launches New COE Program to Focus on Rare-Disease Populations


The nation's largest independent specialty pharmacy has launched a new Rare Disease Center of Excellence (COE) program custom-built to serve patients with orphan diseases.

FLINT, Mich., Dec. 16, 2015 /PRNewswire/ -- Diplomat Pharmacy, Inc. (NYSE: DPLO) announced today its new Rare Disease Center of Excellence (COE) program to manage a high-touch service offering specifically for rare-disease patients.

Diplomat Specialty Pharmacy

The Rare Disease COE is custom-built to serve the unique needs of rare-disease populations, with a team of specialists who establish one-on-one relationships with patients. This COE program offers patients a single point of contact, a direct-line to a specialist. High-touch communication allows the care team to work closely with patients, caregivers and physicians, and break down the barriers to medication access and adherence.

"To support patients in their therapy, as part of our pharmaceutical care we also have an enhanced nursing component," said Gary Kadlec, president of Diplomat. "We recently added an associate director of nursing to our team to focus our high-touch services and drive more nursing care intervention in one-on-one discussions with patients, for care that is truly customized to a patient's needs."

"We've launched new efforts to amplify patient support and leverage our team's expertise in managing orphan and ultra-orphan therapies," Kadlec said. "Our new model improves efficiencies and helps promote therapy access for patients, expedites new medicinal launches and eases the burden for every patient on that journey."

"You have given me my life back," said a Diplomat patient suffering with periodic paralysis, one of the disease states served within the new program. "I mean you have given me every day that I have for the rest of my life."

To learn more about Diplomat, visit www.diplomat.is.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.

About Diplomat

Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients, and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.

Kali Lucas, Public Relations Coordinator
810.768.9580 | press@diplomat.is

Gary Rice, RPh, MS, MBA, CSP,
Senior Vice President, Clinical Services,
Education, and Human Resources 
810.768.9863 | grice@diplomat.is

Logo - http://photos.prnewswire.com/prnh/20140928/148820

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/diplomat-launches-new-coe-program-to-focus-on-rare-disease-populations-300194097.html

SOURCE Diplomat Pharmacy, Inc.


+0.01 +0.25% $ 3.99 Volume: 481,394 Common Stock | 20 minute delay January 21, 2020

Investor Contact

Terri Anne Powers,
Vice President, Investor Relations
Diplomat Pharmacy Inc.
Phone: 312.889.5244

Email Now